natgillin/translations-raw huggingface dataset:
Other medicines and Adempas Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, in particular, medicines used for: - high blood pressure or heart disease (such as nitrates and amyl nitrite) in any form, as you must not take those medicines together with Adempas. 
Druga zdravila in zdravilo Adempas Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo, predvsem zdravila, ki se uporabljajo pri: - visokem krvnem tlaku ali boleznih srca (npr. nitrati in amilnitrit) v kakršni koli obliki, saj teh zdravil ne smete jemati sočasno z zdravilom Adempas, - visokem krvnem tlaku v pljučnih žilah (pljučnih arterijah), saj določenih zdravil (sildenafil in tadalafil) ne smete jemati sočasno z zdravilom Adempas.
you feel short of breath during treatment with this medicine, this can be caused by a build-up of fluid in the lungs. 
- če ste zasopli med zdravljenjem s tem zdravilom, kar je lahko posledica kopičenja tekočine v pljučih.
In a reproduction toxicity study in rats, decreased testes weights were seen, but there were no effects on fertility (see section 5.3). 
V študiji vpliva na sposobnost razmnoževanja pri podganah so opazili zmanjšano maso mod, vendar učinkov na plodnost niso opazili (glejte poglavje 5.3).
Approximately 9-44% of the administered dose was found as unchanged riociguat in faeces. 
Približno 9 - 44 % uporabljenega odmerka riociguata se je v nespremenjeni obliki izločilo z blatom.
With a systemic clearance of about 3-6 L/h, riociguat can be classified as a low-clearance drug. 
Sistemski očistek je približno 3 - 6 l/h, kar riociguat uvršča med zdravila z majhnim očistkom.
The adverse reactions reported with Adempas are listed in the table below by MedDRA system organ class and by frequency. 
Neželeni učinki, o katerih so poročali pri zdravljenju z zdravilom Adempas, so navedeni v spodnji preglednici po organskih sistemih klasifikacije MedDRA in pogostnosti.
A randomised, double-blind, multi-national, placebo controlled, phase III study (PATENT-1) was conducted in 443 adult patients with PAH (riociguat individual dose titration up to 2.5 mg three times daily: n=254, placebo: n=126, riociguat “capped” dose titration (CT) up to 1.5 mg (exploratory dose arm, no statistical testing performed; n=63)). 
V randomizirano, dvojno slepo, multinacionalno, s placebom nadzorovano študijo faze III (PATENT-1) je bilo vključenih 443 odraslih bolnikov s PAH (titriranje odmerka riociguata za posameznega bolnika do 2,5 mg trikrat na dan: n = 254, placebo: n = 126, navzgor omejeno titriranje odmerka riociguata (CT - ''capped'' dose titration) do 1,5 mg (skupina za določanje odmerka, statistična analiza ni bila izvedena; n = 63)).
Concomitant use with other CYP and P-gp/BCRP inhibitors 
Sočasna uporaba z drugimi zaviralci CYP in P-gp/BCRP
If at any time during the up-titration phase systolic blood pressure decreases below 95 mmHg and the patient shows signs or symptoms of hypotension the current dose should be decreased by 0.5 mg three times daily. 
Če se kadar koli v obdobju titriranja odmerka sistolični krvni tlak zniža pod 95 mm Hg in ima bolnik znake ali simptome hipotenzije, je treba trenutni odmerek zdravila zmanjšati za 0,5 mg trikrat na dan.
Women of childbearing potential must use effective contraception during treatment with Adempas. 
Ženske v rodni dobi morajo med zdravljenjem z zdravilom Adempas uporabljati učinkovito kontracepcijsko metodo.
Riociguat (2.5 mg three times per day) did not have a clinically meaningful effect on the plasma levels of combined oral contraceptives containing levonorgestrel and ethinyl estradiol when concomitantly administered to healthy female subjects. 
Pri zdravih ženskah riociguat (2,5 mg trikrat na dan) ni klinično pomembno vplival na plazemske vrednosti kombiniranih peroralnih kontraceptivov, ki vsebujejo levonorgestrel in etinilestradiol, če je bil uporabljen sočasno.
It is recommended to monitor these patients for signs and symptoms of hypotension (see sections 4.2 and 4.4). 
Priporočljivo je spremljanje teh bolnikov glede znakov in simptomov hipotenzije (glejte poglavji 4.2 in 4.4).
In a fertility study in rats, decreased testes weights occurred at systemic exposure of about 7-fold of human exposure, whereas no effects on male and female fertility were seen. 
V študiji vpliva na plodnost pri podganah so opazili zmanjšano maso mod pri sistemski izpostavljenosti, ki je bila približno 7-krat večja od izpostavljenosti pri ljudeh, pri čemer pa učinkov na plodnost samcev ali samic niso opazili.
Patients were either treatment-naïve (50%) or pre-treated with ERA (43%) or a prostacyclin analogue (inhaled (iloprost), oral (beraprost) or subcutaneous (treprostinil); 7%) and had been diagnosed with idiopathic or heritable PAH (63.4%), PAH associated with connective tissue disease (25.1%) and congenital heart disease (7.9%). 
Bolniki so bili predhodno nezdravljeni (50 %) ali pa so se predhodno zdravili z antagonisti endotelinskih receptorjev (43 %) ali z analogom prostaciklina (inhalacija (iloprost), peroralna uporaba (beraprost) ali subkutana uporaba (treprostinil); 7 %); PAH je bila opredeljena kot idiopatska ali dedna (63,4 %), PAH, povezana z boleznijo veziva (25,1 %) in prirojeno boleznijo srca (7,9 %).
A randomised, double blind, placebo-controlled phase II study (RISE-IIP) to evaluate the efficacy and safety of riociguat in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) was terminated early due to an increased risk of mortality and serious adverse events in patients treated with riociguat and a lack of efficacy. 
faze (RISE-IIP), ki je vrednotila učinkovitost in varnost riociguata pri bolnikih s simptomatsko pljučno hipertenzijo, povezano z idiopatsko intersticijsko pljučnico (PH-IIP), je bila predčasno zaključena zaradi povečanega tveganja za umrljivost in resne neželene učinke pri bolnikih, ki so se zdravili z riociguatom, in zaradi pomanjkanja učinkovitosti.
Adempas is only prescribed for certain forms of PAH, i.e. idiopathic PAH (the cause of PAH is unknown), heritable PAH and PAH caused by connective tissue disease. 
Zdravilo Adempas se predpisuje samo za zdravljenje določenih oblik pljučne arterijske hipertenzije, tj. idiopatske PAH (vzrok bolezni je neznan), dedne PAH in PAH, ki jo je povzročila bolezen veziva.
A randomised, double-blind, multi-national, placebo controlled, phase III study (CHEST-1) was conducted in 261 adult patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) (72%) or persistent or recurrent CTEPH after pulmonary endarterectomy (PEA; 28%). 
V randomizirano, dvojno slepo, multinacionalno, s placebom nadzorovano študijo faze III (CHEST-1), je bilo vključenih 261 odraslih bolnikov z neoperabilno kronično trombembolično pljučno hipertenzijo (CTEPH) (72 %) ali perzistentno ali ponovno CTEPH po pljučni endarteriektomiji (PEA; 28 %).
Riociguat is a type of medicine called a guanylate cyclase (sGC)-stimulator. 
Riociguat je vrsta zdravila, ki se imenuje spodbujevalec topne gvanilat-ciklaze (sGC - soluble guanylate cyclase).
No specific studies with riociguat in humans have been conducted to evaluate effects on fertility. 
Posebnih študij za oceno učinkov riociguata na plodnost pri ljudeh niso izvedli.
Due to the high plasma protein binding riociguat is not expected to be dialysable. 
Zaradi visoke stopnje vezave na plazemske proteine ni pričakovati, da bi se riociguat dializiral.
If you are stopping Adempas to change to another medicine called a PDE5 inihibitor (e.g. sildenafil or tadalafil) you must wait at least 24 hours from your last dose of Adempas before you take the PDE5 inhibitor. 
Če ste prenehali z uporabo zdravila Adempas, da bi ga zamenjali z drugim zdravilom, ki se imenuje zaviralec PDE5 (tj. sildenafil ali tadalafil), mora miniti vsaj 24 ur od zadnjega odmerka zdravila Adempas, preden vzamete zaviralec PDE5.
The probability of survival at 1 year was 97%, at 2 years 93% and at 3 years 89%. 
Verjetnost preživetja po enem letu je bila 97 %, po dveh letih 93 %, in po treh letih 89 %.
If you are stopping tadalafil, you must wait at least 48 hours before you take Adempas. 
Če prenehate z uporabo tadalafila, morate počakati vsaj 48 ur, preden vzamete zdravilo Adempas.
INFORMATION IN BRAILLE Adempas 0.5 mg, 1 mg, 1.5 mg, 2 mg or 2.5 mg 
PODATKI V BRAILLOVI PISAVI Adempas 0,5 mg, 1 mg, 1,5 mg, 2 mg ali 2,5 mg
The probability of survival at 1 year was 97%, at 2 years 93% and at 3 years 88%. 
Verjetnost preživetja po enem letu je bila 97 %, po dveh letih 93 %, in po treh letih 88 %.
Film-coat: hydroxypropylcellulose, hypromellose 3 cP, propylene glycol (E 1520) and titanium dioxide (E 171). 
Filmska obloga: hidroksipropilceluloza, hipromeloza 3 cP, propilenglikol (E 1520) in titanov dioksid (E 171)
If you are transitioning between sildenafil or tadalafil and Adempas If you are stopping sildenafil, you must wait at least 24 hours before you take Adempas. 
Če prehajate med zdravljenjem s sildenafilom ali tadalafilom in zdravilom Adempas Če prenehate z uporabo sildenafila, morate počakati vsaj 24 ur, preden vzamete zdravilo Adempas.
Very common: may affect more than 1 in 10 people - headache - dizziness - indigestion (dyspepsia) - swelling of limbs (oedema peripheral) - diarrhoea - feeling or being sick (nausea and vomiting) 
Zelo pogosti: pojavijo se lahko pri več kot 1 od 10 bolnikov - glavobol - omotičnost - prebavne motnje (dispepsija) - oteklost okončin (periferni edem) - driska - siljenje na bruhanje ali bruhanje (navzea in bruhanje)
Inhibitors for the UDP-Glykosyltransferases (UGT) 1A1 and 1A9 may potentially increase the exposure of the riociguat metabolite M1, which is pharmacologically active (pharmacological activity: 1/10th to 1/3rd of riociguat). 
Zaviralci UDP-glikoziltransferaze (UGT) 1A1 in 1A9 lahko zvečajo izpostavljenost farmakološko aktivnemu presnovku M-1 (farmakološka aktivnost: 1/10 do 1/3 aktivnosti riociguata).
• 90 tablets: five transparent blisters of 18 tablets each. 
• 90 tablet: pet prozornih pretisnih omotov po 18 tablet
The tablet may be crushed and mixed with water or a soft food, such as apple sauce, immediately before you take it. 
Tableto lahko tik pred uporabo zdrobite in zmešate z vodo ali mehko hrano, kot je na primer jabolčna čežana.
Further exploratory subgroup analysis revealed a treatment effect of 26 m, (95% CI: 5 m to 46 m) in patients pre-treated with ERAs (n=167) and a treatment effect of 101 m (95% CI: 27 m to 176 m) in patients pre-treated with prostacyclin analogues (n=27). 
V nadaljnji analizi preučevanih podskupin so ugotovili podaljšanje prehojene razdalje v dolžini 26 m, (95-odstotni IZ: 5 m do 46 m) pri bolnikih, predhodno zdravljenih z ERA (n = 167) in 101 m (95-odstotni IZ: 27 m do 176 m) pri bolnikih, predhodno zdravljenih z analogi prostaciklina (n = 27).
Riociguat-treated patients experienced a significant delay in time to clinical worsening versus placebo-treated patients (p = 0.0046; Stratified log-rank test) (see table 6). 
Pri bolnikih, zdravljenih z riociguatom, se je čas do kliničnega poslabšanja značilno podaljšal v primerjavi z bolniki, ki so prejemali placebo (p = 0,0046; stratificirani test log-rank) (glejte preglednico
Adempas is used in either of two types of pulmonary hypertension: 
Zdravilo Adempas se uporablja za zdravljenje dveh oblik pljučne hipertenzije.
Non-clinical data show undesirable effects on growing bone (see section 5.3). 
Predklinični podatki kažejo neželene učinke na rast in razvoj kosti (glejte poglavje 5.3).
Co-administration of the antacid aluminium hydroxide / magnesium hydroxide reduced riociguat mean AUC by 34% and mean Cmax by 56% (see section 4.2). 
Sočasna uporaba antacida aluminijevega hidroksida/magnezijevega hidroksida zmanjša povprečno AUC riociguata za 34 % in povprečno Cmax riociguata za 56 % (glejte poglavje 4.2).
Table 1: Adverse reactions reported with Adempas in the phase III studies MedDRA 
Preglednica 1: Neželeni učinki zdravila Adempas, o katerih so poročali v študijah faze III
Table 5: Effects of riociguat in PATENT-1 on PVR and NT-proBNP at last visit PVR 
Preglednica 5: Učinki riociguata v študiji PATENT-1 na PVR in NT-proBNP pri zadnjem obisku
The concomitant use of riociguat with other cumarin-derivatives (e.g. phenprocoumon) is also not expected to alter prothrombin time. 
Ni pričakovati, da bi sočasna uporaba riociguata z drugimi derivati kumarina (npr. fenprokumon) vplivala na protrombinski čas.
Patients treated with riociguat showed significant improvement in Borg CR 10 dyspnoea score (mean change from baseline (SD): riociguat -0.4 (2), placebo 0.1 (2); p = 0.0022). 
Pri bolnikih, zdravljenih z riociguatom, so opazili značilno izboljšanje glede na oceno dispneje CR10 po Borgovi lestvici (povprečna sprememba od izhodiščne vrednosti (SD): riociguat -0,4 (2), placebo 0,1 (2); p = 0,0022).
In the longterm extension, more patients who switched from the placebo group to riociguat (21%) died than those who continued in the riociguat group (3%). 
Pri dolgoročnem podaljšanju je umrlo več bolnikov, ki so najprej prejemali placebo in nato prešli na zdravljenje z riociguatom (21 %) v primerjavi s tistimi, ki so začeli in nadaljevali zdravljenje z riociguatom (3 %).
Tadalafil must be discontinued at least 48 hours prior to administration of riociguat. 
Z uporabo tadalafila je treba prenehati vsaj 48 ur pred uporabo riociguata.
Riociguat restores the NO-sGC-cGMP pathway resulting in a significant improvement of pulmonary vascular haemodynamics and an increase in exercise ability. 
Riociguat ponovno vzpostavi pot NO-sGC-cGMP, kar pomembno izboljša pljučno-žilno hemodinamiko in poveča telesno zmogljivost.
There is a direct relationship between riociguat plasma concentration and haemodynamic parameters such as systemic and pulmonary vascular resistance, systolic blood pressure and cardiac output. 
Med koncentracijami riociguata v plazmi in hemodinamskimi parametri, kot so sistemski žilni upor in upor v pljučnem žilju, sistolični krvni tlak in iztis srca, obstaja neposredna povezava.
Moderate passage across the placental barrier was observed. 
Opazili so zmerno prehajanje skozi posteljico.
Based on in vitro data riociguat and its main metabolite are substrates of the transporter proteins P-gp (P-glycoprotein) and BCRP (breast cancer resistance protein). 
Glede na podatke in vitro je znano, da sta riociguat in njegov glavni presnovek substrata prenašalnih proteinov P-gp (P-glikoprotein) in BCRP (protein odpornosti na raka dojke).
You should be aware of the side effects of this medicine before driving or using machines (see section 4). 
Preden začnete voziti ali uporabljati stroje, morate poznati neželene učinke tega zdravila (glejte poglavje 4).
When NO binds to sGC, the enzyme catalyses synthesis of the signalling molecule cyclic guanosine monophosphate (cGMP). 
Ko se dušikov oksid veže na sGC, encim katalizira sintezo signalne molekule ciklični gvanozin monofosfat (cGMP - cyclic guanosine monophosphate).
- if you have severe liver problems (severe hepatic impairment, Child Pugh C). 
- če imate hude težave z jetri (hudo jetrno okvaro, Child Pugh C).
If not tolerated, dose reduction should be considered at any time. 
Če bolnik zdravila ne prenaša, se lahko odmerek kadar koli zmanjša.
A dose decrease may be required in patients who stop smoking. 
Pri bolnikih, ki prenehajo kaditi, bo morda treba odmerek zmanjšati.
Non-clinical data revealed no specific hazard for humans based on conventional studies of safety pharmacology, single dose toxicity, phototoxicity, genotoxicity and carcinogenicity. 
Predklinični podatki na osnovi običajnih študij farmakološke varnosti, toksičnosti po enkratnem odmerku, fototoksičnosti, genotoksičnosti in kancerogenega potenciala ne kažejo posebnega tveganja za ljudi.
In vitro, abacavir, rilpivirine, efavirenz, ritonavir, cobicistat and elvitegravir inhibited CYP1A1 and the metabolism of riociguat in the order listed with abacavir as the strongest inhibitor. 
In vitro, abakavir, rilpivirin, efavirenz, ritonavir, kobicistat in elvitegravir so zavrli CYP1A1 in presnovo riociguata v navedenem vrstnem redu; abakavir je bil najmočnejši zaviralec.
- nausea, vomiting (feeling or being sick) (such as granisetron). 
- lajšanju navzee (občutek siljenja na bruhanje), bruhanja (npr. granisetron).
There is increased riociguat exposure in these patients (see section 5.2). 
Pri teh bolnikih je izpostavljenost riociguatu večja (glejte poglavje 5.2).
In CTEPH, the blood vessels of the lung are blocked or narrowed with blood clots. 
Pri CTEPH so krvne žile v pljučih zamašene ali zožene zaradi krvnih strdkov.
Overall, mean dose- and weight- normalised exposure values for riociguat were higher in subjects with renal impairment compared to subjects with normal renal function. 
Na splošno so bile povprečne vrednosti izpostavljenosti riociguatu, normalizirane glede na odmerek in telesno maso, večje pri osebah z ledvično okvaro v primerjavi z osebami z normalnim delovanjem ledvic.
If you are breast-feeding or planning to breast-feed, ask your doctor or pharmacist for advice before taking this medicine because it might harm your baby. 
Če dojite ali nameravate dojiti, se pred uporabo tega zdravila posvetujte z zdravnikom ali farmacevtom, saj lahko to zdravilo škoduje vašemu otroku.
N-demethylation, catalysed by CYP1A1, CYP3A4, CYP3A5 and CYP2J2 is the major biotransformation pathway of riociguat leading to its major circulating active metabolite M-1 (pharmacological activity: 1/10th to 1/3rd of riociguat) which is further metabolised to the pharmacologically inactive N-glucuronide. 
N-demetilacija, ki jo katalizirajo CYP1A1, CYP3A4, CYP3A5 in CYP2J2, je glavna pot biotransformacije riociguata, ki privede do nastanka glavnega aktivnega presnovka M-1 v krvnem obtoku (farmakološka aktivnost: 1/10 do 1/3 aktivnosti riociguata) in nadalje do farmakološko neaktivnega N-glukuronida.
Change in WHO Functional Class 
Sprememba funkcijskega razreda po klasifikaciji SZO
In a clinical study the highest dose of Adempas (2.5 mg tablets three times daily) potentiated the blood pressure lowering effect of sublingual nitroglycerin (0.4 mg) taken 4 and 8 hours after intake. 
V klinični študiji je največji odmerek zdravila Adempas (2,5 mg tablete trikrat na dan) povečal hipotenzivni učinek nitroglicerina (0,4 mg), vzetega sublingvalno, 4 do 8 ur po zaužitju zdravila Adempas.
How to store Adempas 6. 
Shranjevanje zdravila Adempas 6.
Approximately 4-19% of the administered dose was excreted as unchanged riociguat via the kidneys. 
Približno 4 - 19 % uporabljenega odmerka riociguata se je v nespremenjeni obliki izločilo skozi ledvice.
Survival in patients of WHO functional class II at baseline at 1, 2 and 3 years was 98%, 96% and 93% respectively, and for patients of WHO functional class III at baseline was 96%, 91% and 84% respectively. 
funkcijski razred po klasifikaciji SZO, je bilo po enem, dveh in treh letih zdravljenja 98 %, 96 % in 93 %, medtem ko je bilo preživetje bolnikov, ki so bili na začetku zdravljenja razvrščeni v III. funkcijski razred, 96 %, 91 % in 84 %.
Adempas 2 mg and 2.5 mg tablets also contains iron oxide yellow (E172) and iron oxide red (E 172). 
Tablete Adempas 2 mg in 2,5 mg vsebujejo rumeni železov oksid (E 172) in rdeči železov oksid (E 172).
To mitigate the risk of hypotension, consider dose reduction and monitoring for signs and symptoms of hypotension (see sections 4.2 and 4.5). 
Za zmanjšanje tveganja za hipotenzijo mora razmisliti o zmanjšanju odmerka in spremljati znake in simptome hipotenzije (glejte poglavji 4.2 in 4.5).
Treatment-naïve patients (n=189) improved by 38 m, and pre-treated patients (n=191) by 36 m (ITT analysis, see table 4). 
Podaljšanje prehojene razdalje pri predhodno nezdravljenih bolnikih (n = 189) je bilo 38 m, pri predhodno zdravljenih bolnikih (n = 191) pa 36 m (analiza glede na namero zdravljenja (ITT), glejte preglednico 4).
Lack of pharmacokinetic interactions between riociguat and the CYP2C9 substrate warfarin was demonstrated in vivo. 
In vivo je dokazano, da ni farmakokinetičnih interakcij med riociguatom in varfarinom, ki je substrat CYP2C9.
Table 4: Effects of riociguat on 6MWD in PATENT-1 at last visit Entire patient population Riociguat IDT (n=254) 
Preglednica 4: Učinki riociguata na 6MWD v študiji PATENT-1 pri zadnjem obisku Celotna populacija bolnikov riociguat IDT (n = 254)
In cirrhotic patients (non-smokers) with mild hepatic impairment (classified as Child Pugh A) riociguat mean AUC was increased by 35% compared to healthy controls, which is within normal intra-individual variability. 
Pri bolnikih s cirozo (nekadilcih) z blago jetrno okvaro (Child Pugh A) se je povprečni AUC za riociguat povečal za 35 % v primerjavi z zdravimi osebami v primerjalni skupini, kar je znotraj interindividualne variabilnosti.
Tablet core: cellulose microcrystalline, crospovidone (type B), hypromellose 5 cP, lactose monohydrate, magnesium stearate and sodium laurilsulfate (see end of section 2 for further information on lactose). 
Jedro tablete: mikrokristalna celuloza, krospovidon (tip B), hipromeloza 5 cP, laktoza monohidrat, magnezijev stearat in natrijev lavrilsulfat (glejte zadnji odstavek v poglavju 2 za dodatne informacije o laktozi).
PVR= pulmonary vascular resistance 
PVR (pulmonary vascular resistance)- upor v pljučnem žilju
• Periodic safety update reports 
- Redno posodobljena poročila o varnosti zdravila (PSUR)
Concomitant use with medicinal products increasing gastric pH 
Sočasna uporaba z zdravili, ki povečajo pH v želodcu
The recommended starting dose is a 1-mg tablet taken 3 times a day for 2 weeks. 
Priporočeni začetni odmerek je 1 tableta po 1 mg, trikrat na dan v obdobju 2 tednov.
Mean change from baseline for the overall population (N=237) was 57 m at 6 months (n=218), 51 m at 9 months (n=219), 52 m at 12 months (n=209) and 48 m at 24 months (n=193). 
Pri celotni populaciji (n = 237) je bila povprečna sprememba od izhodiščne vrednosti do 6. meseca 57 m (n = 218), do 9. meseca 51 m (n = 219), do 12. meseca 52 m (n = 209) in do 24. meseca 48 m (n = 193).
These antacid medicines should be taken at least two hours before or one hour after taking 
Te antacide morate vzeti vsaj dve uri pred ali eno uro po zaužitju zdravila Adempas.
Riociguat must be discontinued at least 24 hours prior to administration of a PDE5 inhibitor. 
Z uporabo riociguata je treba prenehati vsaj 24 ur pred uporabo zaviralcev PDE5.
Concomitant use of riociguat with PDE5 inhibitors (such as sildenafil, tadalafil, vardenafil) is contraindicated (see sections 4.2 and 4.3). 
Sočasna uporaba riociguata z zaviralci PDE5 (kot so sildenafil, tadalafil, vardenafil) je kontraindicirana (glejte poglavji 4.2 in 4.3).
From the recombinant CYP isoforms investigated in vitro CYP1A1 catalysed formation of riociguat's main metabolite most effectively. 
Med in vitro preučevanimi rekombinantnimi izooblikami CYP, je CYP1A1 najbolj učinkovito kataliziral nastajanje glavnega presnovka riociguata.
Pack sizes: 42, 84, 90 or 294 film-coated tablets. 
PRETISNI OMOT - PAKIRANJA Z 42, 84, 90, 294 FILMSKO OBLOŽENIMI TABLETAMI
Placebo-adjusted difference (dyn·s·cm-5) 
glede na placebo prilagojena razlika (dyn·s·cm-5)
Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease (see section 5.1). 
Učinkovitost zdravila je bila dokazana pri bolnikih s PAH, tudi pri bolnikih z etiologijo idiopatske ali dedne PAH ali PAH, povezane z boleznijo veziva (glejte poglavje 5.1).
The concomitant use of riociguat with strong CYP3A4 inducers (e.g. phenytoin, carbamazepine, phenobarbitone or St. John's Wort) may also lead to decreased riociguat plasma concentration. 
Tudi sočasna uporaba riociguata z močnimi induktorji CYP3A4 (npr. fenitoin, karbamazepin, fenobarbiton ali šentjanževka) lahko povzroči zmanjšanje koncentracije riociguata v plazmi.
Riociguat did not potentiate the bleeding time caused by acetyl-salicylic acid or affect the platelet aggregation in humans. 
Riociguat pri ljudeh ni dodatno podaljšal časa krvavitve po uporabi acetilsalicilne kisline, ali vplival na agregacijo trombocitov.